Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

T. K. Olesen · SciRah

Researcher profile · Semantic Scholar

T. K. Olesen

Share profile

T. K. Olesen — researcher profile on SciRah

h-index: 12
Works: 50
Citations: 1,732

Most-cited papers

The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancer
L. Klotz, L. Boccon-Gibod, N. Shore, C. Andreou +5 more
2008BJU International567 citations
Semantic Scholar
Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist.
P. Albertsen, L. Klotz, B. Tombal, J. Grady +2 more
2014European Urology335 citations
Semantic Scholar
A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.
E. Crawford, B. Tombal, K. Miller, L. Boccon-Gibod +6 more
2011Journal of Urology146 citations
Semantic Scholar
A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America.
M. Gittelman, P. Pommerville, B. Persson, J. Jensen +1 more
2008Journal of Urology101 citations
Semantic Scholar
Cardiovascular Safety of Degarelix versus Leuprolide in Patients with Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial
R. Lopes, C. Higano, S. Slovin, A. Nelson +14 more
2021Circulation92 citations Open access
Semantic Scholar
Cardiovascular Safety of Degarelix: Results From a 12-Month, Comparative, Randomized, Open Label, Parallel Group Phase III Trial in Patients With Prostate Cancer
M. Smith, L. Klotz, B. Persson, T. K. Olesen +1 more
2010Journal of Urology79 citations Open access
Semantic Scholar
Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12‐month, comparative, phase III study
F. Schröder, B. Tombal, K. Miller, L. Boccon-Gibod +5 more
2009BJU International78 citations Open access
Semantic Scholar
Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix.
E. Crawford, N. Shore, J. Moul, B. Tombal +7 more
2014Urology60 citations
Semantic Scholar
Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer
C. Melloni, S. Slovin, A. Blemings, S. Goodman +9 more
2020JACC CardioOncology44 citations Open access
Semantic Scholar
The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients.
J. Damber, T. Tammela, P. Iversen, P. Abrahamsson +4 more
2012Urology31 citations
Semantic Scholar
Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer
J. de la Rosette, R. Davis, D. Frankel, T. K. Olesen
2011International journal of clinical practice23 citations Open access
Semantic Scholar
Follicle-Stimulating Hormone Receptor Expression in Endometriotic Lesions and the Associated Vasculature
B. Robin, François Planeix, X. Sastre-Garau, C. Pichon +3 more
2016Reproductive Sciences21 citations
Semantic Scholar
Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses
D. Ulmert, A. Vickers, H. Scher, C. Becker +5 more
2012Clinical Chemistry and Laboratory Medicine12 citations Open access
Semantic Scholar
P109 Efficacy and safety of a 3-monthly depot formulation of degarelix compared with goserelin in prostate cancer
B. Tombal, T. Tammela, J. Wolff, H. Payne +6 more
201211 citations
Semantic Scholar
Systematic review of proposed definitions of nocturnal polyuria and population-based evidence of their diagnostic accuracy
T. K. Olesen, Marie-Astrid Denys, J. Vande Walle, K. Everaert
2018Acta Clinica Belgica10 citations
Semantic Scholar
670 SWITCHING FROM LEUPROLIDE TO DEGARELIX VS CONTINUOUS DEGARELIX TREATMENT – EFFECTS ON LONG-TERM PROSTATE-SPECIFIC ANTIGEN CONTROL
E. Crawford, J. Moul, N. Shore, T. K. Olesen +1 more
20109 citations
Semantic Scholar
Identifying men with global polyuria on a nocturnal‐only voiding diary
Thomas F. Monaghan, Syed N. Rahman, D. Bliwise, Kyle P. Michelson +8 more
2020Neurourology and Urodynamics8 citations
Semantic Scholar
Assessment of the Most Impactful Combination of Factors Associated with Nocturia and to Define Nocturnal Polyuria by Multivariate Modelling
T. K. Olesen, Jérôme Paul, P. Gramme, M. Drake +2 more
2020Journal of Clinical Medicine8 citations Open access
Semantic Scholar
Prostate-specific antigen (PSA) progression-free survival (PFS): A comparison of degarelix versus leuprolide in patients with prostate cancer.
N. Shore, J. Moul, E. Crawford, E. A. van der Meulen +2 more
2011Journal of Clinical Oncology8 citations
Semantic Scholar
DEGARELIX COMPARED TO LEUPROLIDE DEPOT 7.5 MG IN A 12- MONTH RANDOMISED, OPEN-LABEL, PARALLEL-GROUP PHASE III STUDY IN PROSTATE CANCER PATIENTS
L. Boccon-Gibod, L. Klotz, H. Schröder, C. Andreou +4 more
20088 citations
Semantic Scholar
904Degarelix - a phase 11 multicentre, randomized dose-escalating study testing a novel gnrh receptor blocker in prostate cancer patients
T. Tammela, P. Iversen, J. Johansson, B. Persson +2 more
20058 citations
Semantic Scholar
Follicle-stimulating hormone receptor expression in advanced atherosclerotic plaques
Nicolae Ghinea, E. Liehn, J. Grommes, Diane Dalila Delattre +1 more
2024Scientific Reports7 citations Open access
Semantic Scholar
23 LONG-TERM EVALUATION OF DEGARELIX, A GONADOTROPHIN-RELEASING HORMONE (GNRH) RECEPTOR BLOCKER, INVESTIGATED IN A MULTICENTRE RANDOMISED STUDY IN PROSTATE CANCER (CAP) PATIENTS
H. Van Poppel, J. de la Rosette, B. Persson, T. K. Olesen
20076 citations
Semantic Scholar
In vivo pharmacodynamic evaluation of the novel nystatin derivative BSG005 in the invasive candidiasis and invasive pulmonary aspergillosis mouse models
A. Lepak, J. Massey, R. Zarnowski, T. K. Olesen +2 more
2024Antimicrobial Agents and Chemotherapy5 citations Open access
Semantic Scholar
Development of a multivariate prediction model for nocturia, based on urinary tract etiologies
T. K. Olesen, Marie-Astrid Denys, A. Goessaert, E. Bruneel +5 more
2019International journal of clinical practice5 citations Open access
Semantic Scholar
Comparision of the risk of cardiovascular events and death in patients treated with degarelix compared with LHRH agonists.
P. Albertsen, J. Nilsson, L. Klotz, H. Payne +4 more
2013Journal of Clinical Oncology5 citations
Semantic Scholar
38 DEGARELIX VS. LEUPROLIDE TREATMENT IN PATIENTS WITH ADVANCED PROSTATE CANCER: PSA FAILURES DURING A RANDOMISED, PHASE III TRIAL (CS21)
B. Tombal, K. Miller, L. Boccon-Gibod, F. Schröder +3 more
20095 citations
Semantic Scholar
A ONE-YEAR, MULTICENTRE, RANDOMISED STUDY OF DEGARELIX, A GONADATROPHIN–RELEASING HORMONE (GNRH) RECEPTOR BLOCKER, IN PROSTATE CANCER PATIENTS
H. Van Poppel, J. de la Rosette, B. Persson, J. Jensen +1 more
20065 citations
Semantic Scholar
781 ANDROGEN DEPRIVATION THERAPY BY A GONADOTROPIN RELEASING HORMONE ANTAGONIST, DEGARELIX, LOWERS THE RISK OF CARDIOVASCULAR EVENTS OR DEATH WHEN COMPARED TO LUTEINISING HORMONE-RELEASING AGONISTS
P. Albertsen, B. Tombal, T. Wiegel, E. A. van der Meulen +3 more
20134 citations
Semantic Scholar
677 Lower risk of cardiovascular (CV) events and death in men receiving ADT by gonadotropin releasing hormone (GnRH) antagonist, degarelix, compared with luteinising hormone-releasing (LHRH) agonists
B. Tombal, P. Albertsen, A. de la Taille, E. A. van der Meulen +3 more
20134 citations
Semantic Scholar
866 PROSTATE-SPECIFIC ANTIGEN AND SERUM ALKALINE PHOSPHATASE LEVELS IN PROSTATE CANCER PATIENTS RECEIVING DEGARELIX OR LEUPROLIDE
E. Crawford, J. Moul, N. Shore, T. K. Olesen +1 more
20104 citations
Semantic Scholar
40 DEGARELIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: EFFECT IN METASTATIC PATIENTS AS ASSESSED BY SERUM ALKALINE PHOSPHATASE
F. Schröder, L. Boccon-Gibod, B. Tombal, K. Miller +3 more
20094 citations
Semantic Scholar
39 COMPARING TESTOSTERONE AND PSA FOR DIFFERENT BASELINE TESTOSTERONE CONCENTRATIONS DURING INITIATION OF DEGARELIX AND LEUPROLIDE TREATMENT
J. Damber, T. Tammela, P. Abrahamsson, P. Iversen +3 more
20094 citations
Semantic Scholar
N12 SWITCHING FROM LEUPROLIDE TO DEGARELIX VS. CONTINUOUS DEGARELIX TREATMENT – EFFECTS ON LONG-TERM PSA CONTROL
A. Plekhanov, E. Crawford, T. K. Olesen, E. A. van der Meulen +1 more
20103 citations
Semantic Scholar
Degarelix versus leuprolide in prostate cancer patients: new prostate-specific antigen data from a phase III trial (CS21)
B. Tombal, K. Miller, L. Boccon-Gibod, F. Schröder +2 more
20093 citations
Semantic Scholar
MP-08.21: A multicentre, randomised one year dose-finding study of degarelix, a gonadotrophin-releasing hormone (GnRH) receptor blocker, in prostate cancer patients
M. Gittelman, P. Pommerville, B. Persson, T. K. Olesen
20073 citations
Semantic Scholar
Degarelix: A gonadotropin-releasing hormone receptor (GnRH) blocker, tested in two one-year multicenter, randomized, dose-finding studies in prostate cancer patients.
M. Gittelman, P. Pommerville, J. de la Rosette, B. Persson +2 more
2006Journal of Clinical Oncology3 citations
Semantic Scholar
Long-term prostate-specific antigen (PSA) control in prostate cancer (PCa) patients switched from leuprolide to degarelix or receiving continuous degarelix treatment.
N. Shore, J. Moul, E. Crawford, T. K. Olesen +1 more
20102 citations
Semantic Scholar
Degarelix versus leuprolide in patients with metastatic prostate cancer: assessment of serum alkaline phosphatase over time
F. Schroeder, L. Boccon-Gibod, B. Tombal, K. Miller +2 more
20092 citations
Semantic Scholar
Determining the dose of degarelix for effective therapy of prostate cancer patients as investigated by the degarelix study groups
B. Tombal, P. Iversen, H. Van Poppel, T. Tammela +5 more
20062 citations
Semantic Scholar
139 EVALUATION OF THE EFFICACY AND SAFETY OF SWITCHING FROM TREATMENT WITH LEUPROLIDE 1-MONTH DOSING REGIMEN TO DEGARELIX 1-MONTH DOSING REGIMEN IN PROSTATE CANCER (PCA) PATIENTS
J. de la Rosette, R. Davis, B. Persson, T. K. Olesen
20101 citations
Semantic Scholar
582 CARDIOVASCULAR SAFETY OF DEGARELIX: RESULTS FROM A 12-MONTH, COMPARATIVE, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP PHASE III TRIAL IN PROSTATE CANCER PATIENTS
L. Klotz, M. Smith, B. Persson, T. K. Olesen +1 more
20101 citations
Semantic Scholar
Determining the most impactful predictors of nocturia by a multivariate analysis
T. K. Olesen, Jérôme Paul, P. Gramme, M. Drake +2 more
20190 citations
Semantic Scholar
Development of a multivariate prediction model for nocturia, based on the most important etiologies of the urinary tract
S. Roggeman, T. K. Olesen, Marie-Astrid Denys, A. Goessaert +5 more
20180 citations
Semantic Scholar
When is treatment clinically relevant compared to placebo for studies in Nocturia
T. Holm-Larsen, E. A. van der Meulen, J. Nørgaard, T. K. Olesen
20140 citations
Semantic Scholar
Re : Androgen Deprivation Therapy and Risk of Acute Kidney Injury in Patients with Prostate Cancer
F. Lapi, L. Azoulay, M. Niazi, H. Yin +7 more
20140 citations
Semantic Scholar
A method for treating prostate cancer antagonist gonadotropin releasing Harmon (gnrh) degarelix
T. K. Olesen, Бо-Эрик Перссон, Пер Кантор, Дер Мулен Эгберт А. Ван +1 more
20090 citations
Semantic Scholar
A method for the treatment of prostate cancer with the GnRH antagonist degarelix
T. K. Olesen, B. Persson, Per Cantor, Der Meulen Egbert A Van +1 more
20090 citations
Semantic Scholar
METHOD OF TREATING PROSTATE CANCER WITH DEGARELIX THAT IS GONADOTROPIN-RELEASING HORMONE (GnRH) ANTAGONIST
T. K. Olesen, Бо-Эрик Перссон, Пер Кантор, Дер Мулен Эгберт А. Ван +1 more
20090 citations
Semantic Scholar
Rapid elimination kinetics of free PSA and hK2 following initiation of GnRH-antagonist treatment of aggressive Prostate Cancer
D. Ulmert, Angel M. Serio, H. Scher, M. Seandel +4 more
20080 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

B. Persson×31
Invite
B. Persson — researcher profile on SciRah
B. Tombal×13
Invite
B. Tombal — researcher profile on SciRah
J. Jensen×12
Invite
J. Jensen — researcher profile on SciRah
L. Boccon-Gibod×10
Invite
L. Boccon-Gibod — researcher profile on SciRah

×9

Invite

L. Klotz — researcher profile on SciRah

Invite

N. Shore — researcher profile on SciRah

Invite

K. Miller — researcher profile on SciRah

Invite

J. Moul — researcher profile on SciRah

E. A. van der Meulen×7

Invite

E. A. van der Meulen — researcher profile on SciRah

J. de la Rosette×6

Invite

J. de la Rosette — researcher profile on SciRah

Invite

K. Everaert — researcher profile on SciRah

Invite

J. Nilsson — researcher profile on SciRah